It has been proposed that the Akt/GSK-3β signaling pathway might be involved in the pathogenesis of schizophrenia [40] and in the expression of dopamine-associated behaviors [45], and that antipsychotic medication may may exert their beneficial effects, at least in part, by modulating this pathway [40]. Here, AKT1 is linked to schizophrenia.